Galectin-1–driven T cell exclusion in the tumor endothelium promotes immunotherapy resistance

Immune checkpoint inhibitors (ICIs), although promising, have variable benefit in head and neck cancer (HNC). We noted that tumor galectin-1 (Gal1) levels were inversely correlated with treatment response and survival in patients with HNC who were treated with ICIs. Using multiple HNC mouse models,...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:J Clin Invest
Prif Awduron: Nambiar, Dhanya K., Aguilera, Todd, Cao, Hongbin, Kwok, Shirley, Kong, Christina, Bloomstein, Joshua, Wang, Zemin, Rangan, Vangipuram S., Jiang, Dadi, von Eyben, Rie, Liang, Rachel, Agarwal, Sonya, Colevas, A. Dimitrios, Korman, Alan, Allen, Clint T., Uppaluri, Ravindra, Koong, Albert C., Giaccia, Amato, Le, Quynh Thu
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: American Society for Clinical Investigation 2019
Pynciau:
Research Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC6877340/
https://ncbi.nlm.nih.gov/pubmed/31710313
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI129025
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg